The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C

Blood Purification

Volumn 24, Issue 5-6, 2006, Pages 531-537

  Eiselt, Jaromír ^a,b   Racek, Jaroslav ^a   Opatrný Jr , Karel ^a   Trefil, Ladislav ^a   Stehlík, Pavel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Department of Medicine I ^*  (Czech Republic)

Author keywords

Hemodialysis; Intravenous iron; Oxidative stress; Vitamin C level

Indexed keywords

ASCORBIC ACID; FERRIC HYDROXIDE SUCROSE; SODIUM CHLORIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AGED; ARTICLE; ASCORBIC ACID DEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IRON DEFICIENCY; LIPID PEROXIDATION; MALE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; AGED; ANTIOXIDANTS; ASCORBIC ACID; ASCORBIC ACID DEFICIENCY; FEMALE; FERRIC COMPOUNDS; HUMANS; INFUSIONS, INTRAVENOUS; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 33846013246     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096474     Document Type: Article

References (36)

1. Bailie GR, Johnson CA, Mason NA: Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 2000;35:1-12.
2. St Peter WL, Obrador GT, Roberts TL, Collins AJ: Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis 2005;46:650-660.
3. Li S, Foley RN, Gilbertson DT, Liu J, Collins AJ: Clinical factors associated with achieving K/DOQI hemoglobin targets in hemodialysis patients. Int Urol Nephrol 2003;35:399-405.
4. Halliwell B, Gutteridge JM: Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:1-85.
5. Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40:90-103.
6. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003;18:1272-1280.
7. Deicher R, Horl WH: Vitamin C in chronic kidney disease and hemodialysis patients. Kidney Blood Press Res 2003;26:100-106.
8. Morena M, Cristol JP, Canaud B: Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance. Blood Purif 2000;18:191-199.
9. Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993;4:1205-1213.
10. Depner TA, Daugirdas JT: Equations for normalized protein catabolic rate based on two-point modeling of hemodialysis urea kinetics. J Am Soc Nephrol 1996;7:780-785.
11. Margolis SA, Paule RC, Ziegler RG: Ascorbic and dehydroascorbic acids measured in plasma preserved with dithiothreitol or metaphosphoric acid. Clin Chem 1990;10:1750-1755.
12. Margolis SA, Duewer DL: Measurement of ascorbic acid in human plasma and serum: stability, intralaboratory repeatability, and interlaboratory reproducibility. Clin Chem 1996;42:1257-1262.
13. Rumelin A, Fauth U: Determination of ascorbic acid in plasma and urine by high performance liquid chromatography with ultraviolet detection. Clin Chem Lab Med 1999;37:533-536.
14. Jentsch AM, Bachmann H, Furst P, Biesalki HK: Improved analysis of malondialdehyde in human body fluids. Free Rad Biol Med 1996;2:251-256.
15. Deicher R, Ziai F, Cohen G, Mullner M, Horl WH: High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003;64:728-736.
16. Lim PS, Wei YH, Yu YL, Kho B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999;14:2680-2687.
17. Lefevre G, Beljean-Leymarie M, Beyerle F, Bonnefont-Rousselot D, Cristol JP, Therond P: Evaluation of lipid peroxidation by measuring thiobarbituric acid reactive substances. Ann Biol Clin (Paris) 1998;56:395-418.
18. Fumeron C, Nguyen-Khoa T, Saltiel C, Kebede M, Buisson C, Drueke TB, Lacour B, Massy ZA: Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant 2005;20:1874-1879.
19. Carr AC, Frei B: Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr 1999;69:1086-1107.
20. Chen WT, Lin YF, Yu FC, Kao WY, Huang WH, Yan HC: Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels. Am J Kidney Dis 2003;42:158-166.
21. Berger TM, Polidori MC, Dabbagh A, Evans PJ, Halliwell B, Morrow JD, Roberts LJ II, Frei B: Antioxidant activity of vitamin C in iron-overloaded human plasma. J Biol Chem 1997;272:15656-15660.
22. Proteggente AR, Rehman A, Halliwell B, Rice-Evans CA: Potential problems of ascorbate and iron supplementation: pro-oxidant effect in vivo? Biochem Biophys Res Commun 2000;277:535-540.
23. Shi XF, Ding F, Zhu QY, et al: Use of ascorbate-rich dialysate to attenuate oxidative stress in maintenance hemodialysis patients. Ren Fail 2005;27:213-219.
24. Cross JM, Donald AE, Nuttall SL, Deanfield JE, Woolfson RG, Macallister RJ: Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure. Kidney Int 2003;63:1433-1442.
25. Chan D, Irish A, Dogra G: Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology (Carlton) 2005;10:336-340.
26. Rolton HA, McConnell KM, Modi KS, Macdougall AI: The effect of vitamin C intake on plasma oxalate in patients on regular haemodialysis. Nephrol Dial Transplant 1991;6:440-443.
27. Attallah N, Osman-Malik Y, Frinak S, Besarab A: Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 2006;47:644-654.
28. Eiselt J, Racek J, Trefil L, Opatrny K Jr: Effects of a vitamin E-modified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. Artif Organs 2001;25:430-436.
29. Yang CC, Hsu SP, Wu MS, Hsu SM, Chien CT: Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int 2006;69:706-714.
30. Fumeron C, Nguyen-Khoa T, Saltiel C, Kebede M, Buisson C, Drueke TB, Lacour B, Massy ZA: Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant 2005;20:1874-1879.
31. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000;11:539-549.
32. Seligman PA, Schleicher RB: Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 1999;45:898-901.
33. Van Wyck D, Anderson J, Johnson K: Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 2004;19:561-565.
34. Davies KJ, Sevanian A, Muakkassah-Keely SF, Hochstein P: Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 1986; 253:747-754.
35. Sturm B, Laggner H, Ternes N, Goldenberg H, Scheiber-Mojdehkar B: Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron. Kidney Int 2005;67:1161-1170.
36. Esposito BP, Breuer W, Slotki I, Cabantchik ZI: Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002;32(suppl 1):42-49.